Publications
Detailed Information
Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: A phase II trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kang, Won Ki | - |
dc.contributor.author | Kang, Yoon-Koo | - |
dc.contributor.author | Kim, Hugh Chul | - |
dc.contributor.author | Jacques, Christian | - |
dc.contributor.author | Zuber, Emmanuel | - |
dc.contributor.author | Daglish, Byzance | - |
dc.contributor.author | Boudraa, Yvane | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Kim, Noe Kyeong | - |
dc.date.accessioned | 2021-01-31T11:56:16Z | - |
dc.date.available | 2021-01-31T11:56:16Z | - |
dc.date.created | 2020-12-23 | - |
dc.date.issued | 2002-07 | - |
dc.identifier.citation | Japanese Journal of Clinical Oncology, Vol.32 No.7, pp.248-254 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.other | 119633 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173151 | - |
dc.description.abstract | Objective: The aim of the present study was to confirm the efficacy and tolerability of docetaxel 75 mg/m(2) in a population of Korean patients with advanced gastric cancer. Methods: Patients with metastatic or locally recurrent gastric cancer received docetaxel 75 mg/m(2) by intravenous infusion every 3 weeks. Objective response rate was the primary endpoint. Results: Forty-five patients were enrolled. Most showed adenocarcinomas of the gastric antrum and/or body of the stomach. All showed metastases and two-thirds retained the primary tumour. Forty-four patients received at least one docetaxel infusion ('treated' population), with 40 patients evaluable for response. A total of 159 cycles (median three cycles) were administered, with mean duration of treatment 10.9 weeks. The objective response rate in the treated population was 15.9% (17.5% in the per protocol population), with stable disease in 25.0% of patients and progressive disease in 50.0%. Grade 3-4 neutropenia occurred in 36 (81.8%) patients and 36.1% of cycles. However, febrile neutropenia occurred in only two (4.5%) patients and 1.3% of cycles. Grade 3 anorexia, experienced by two patients (4.5%) and during 1.9% of cycles, was the most frequent non-haematological adverse event possibly or probably related to docetaxel. No grade 4 non-haematological events occurred. Conclusion: This study suggests that docetaxel 75 mg/m(2) is active in metastatic or locally recurrent adenocarcinoma with a low incidence of grade 3-4 adverse events. Docetaxel warrants further study in combination regimens for advanced gastric cancer. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: A phase II trial | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1093/jjco/hyf057 | - |
dc.citation.journaltitle | Japanese Journal of Clinical Oncology | - |
dc.identifier.wosid | 000177540000005 | - |
dc.identifier.scopusid | 2-s2.0-0036654749 | - |
dc.citation.endpage | 254 | - |
dc.citation.number | 7 | - |
dc.citation.startpage | 248 | - |
dc.citation.volume | 32 | - |
dc.identifier.sci | 000177540000005 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Kim, Noe Kyeong | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | docetaxel | - |
dc.subject.keywordAuthor | advanced gastric cancer | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.